WHO ICTRP trial
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects…
NL-OMON54921 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON54921 |
|---|---|
| Public title | A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia |
| Scientific title | A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia - IMR-BTL-201 |
| Primary sponsor | IMARA, Inc. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Denmark;Egypt;France;Georgia;Greece;Israel;Italy;Lebanon;Malaysia;Morocco;Netherlands;Tunisia;Turkey;United Kingdom;United States of America |
| Conditions | Beta Thalassemia inherited blood disorder;10038158;Beta Thalassemia;inherited blood disorder |
| Interventions | IMR-687 will be supplied as 100, 150, or 200 mg white tablets to be taken orally. Subjects will be advised to take two IMR-687 tablets orally with food qd for 36 weeks. The different doses of IMR 687 are visually identical in tablet form… |
| Registration date | May 21, 2021 |
| Target size | 15 |
| Secondary IDs | 2019-002989-12;NL73905.056.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: